Jesus del Valle

Business Disruption @Bayerpharma 💛🖤 AcceleRed TeamRed Science4Berlin Hackathons eHealth Startups Pharma yeysus.eth/.tez/.near Exobio Space SciFi Germany Cuba.

[a16z @a16z]

The forward deployed engineer is the hottest job in startups right now, according to @joeschmidtiv.

Here’s why: https://t.co/csx8YcCGBK

[Mnimiy @Mnilax]

https://t.co/4fy9RlQSGy

[Jesus del Valle @yeysus]

Sensitive CAR T cells redefine targetable CD70 expression in solid tumors | Science https://t.co/J1KPV6znHS

[MirrorMe tech @MirrorMeteni7w]

Official Launch | Mirror Me Technology Humanoid Robot Bolt
Founder Enters the Race in Person
No CGI Fully Real Footage
10 m/s — The World’s Fastest Humanoid Robot

[Krish Patel @KrishPatelMD]

@EricTopol Intriguing, Similar observation for use of CART cell therapy in lymphomas from @RShouval

https://t.co/nW1Tyq9FPz

[Eric Topol @EricTopol]

The time of day for cancer immunotherapy is associated with major outcomes. Early is better. Results from a randomized trial of lung cancer, backs up the importance of our circadian rhythm and immune system
https://t.co/bHqUZ3U83O

[Paolo Tarantino @PTarantinoMD]

This is possibly the most controversial finding in immuno-oncology.

The effect size is hard to believe. Though RCTs are hard NOT to believe.

We need a coordinated effort between academia & pharma to look back at prior RCTs to investigate this.

For the safety of our patients.

[The Alliance for Longevity Initiatives (A4LI) @theA4LI]

FDA milestone in aging biology and ophthalmology by @lifebiosciences!

The FDA has cleared their lead candidate ER 100 to enter Phase I clinical trials. ER 100 is a first in class partial epigenetic reprogramming gene therapy designed to address two optic neuropathies, non-arteritic anterior ischemic optic neuropathy (NAION) and primary open angle glaucoma (POAG).

This trial represents an important step for the broader field of aging biology and translational longevity research. Public information about the study, including design and eligibility criteria, is available via https://t.co/TgaAE2Ov5e:
https://t.co/IqAP29q5Ko

We’re also pleased to welcome Dr. David Sinclair (@davidasinclair) and Dr. Michael Ringel (@M_S_Ringel) as speakers at this year’s H-SPAN Summit, where we’ll explore how advances like these intersect with policy, regulation, and responsible translation.

Early bird registration for the H-SPAN Summit is still open: https://t.co/UMOAcjMzUH

[Life Biosciences @lifebiosciences]

We’re pleased to announce we’ve received @FDA IND clearance for our cellular rejuvenation therapy using partial reprogramming for optic neuropathies, including glaucoma and NAION. Read more in our press release: https://t.co/xllr3vKFyZ

[Jesus del Valle @yeysus]

Apúrenseee! Senescence-resistant human mesenchymal progenitor cells counter aging in primates - ScienceDirect https://t.co/mTbL6b2b6f

[Jesus del Valle @yeysus]

‘Autofocus’ glasses can change their lenses in real time: https://t.co/4IPzIMk13p

[Jesus del Valle @yeysus]

WomenEdit – Frauen* schreiben für Wikipedia https://t.co/j5wuzOrW00 #Meetup via @Meetup

[S.E. Robinson, Jr. @SERobinsonJr]

NEURALINK 2025:

- Received FDA Breakthrough Device Designation for its speech restoration technology targeting severe speech impairments.

- Launched its first clinical trial in the Middle East (UAE-PRIME) at Cleveland Clinic Abu Dhabi in partnership with the Department of Health Abu Dhabi.

- Raised $650 million in Series E funding, led by investors including ARK Invest, Sequoia Capital, and Founders Fund, valuing the company at approximately $9 billion.

- Launched clinical trials in the United Kingdom in partnership with University College London Hospitals and Newcastle Hospitals.

- Performed its first procedures outside the United States, implanting devices in two patients with cervical spinal cord injuries at Toronto's University Health Network in Canada.

- Completed two surgeries in Canada, marking the first non-US procedures.

- The first UK participant, Paul, received an implant and controlled a computer with thoughts hours after surgery at University College London Hospitals.

- Convoy project testing with participants controlling robotic arms with their BCIs.

- Introduced an upgraded next-generation surgical robot with improved electrode thread insertion time of 1.5 seconds per thread, greater insertion depths over 50mm, enhances compatibility with 99% of anatomical variations globally, and lowers manufacturing costs for needle cartridges by 95%.

- Announced goals for faster LASIK-like implant procedures in minutes and emphasized flexible electrode threads for safer neuron placement.

- As of now it is estimated that Neuralink as 20 participants. Know are Noland Arbaugh (@ModdedQuad), Alex Conley (@Bcidesign), Bradford Smith (@ALScyborg), Michael Melgarejo, RJ Tanner, Rob Greiner (@greiner_ro52817), Jake Schneider (@PairedWith_P7), Nick Wray (@Telepath_8), Audrey Crews (@NeuraNova9), Paul, and Jon L. Noble (@CheckCanopy).

[Ryan Carson @ryancarson]

Because of LLMs, the only type of people I’d hire now are what I’d call “super-unicorns”

- Developer
- Designer (or great design taste)
- Product-focused (vs feature-focused)
- Marketer
- Agent expert
- High emotional intelligence
- 5+ years experience creating web app products
- Extreme ownership (h/t @jockowillink)

There are very few folks with all these traits …

but I just wouldn’t want to work with someone who didn’t have all these skills/behaviors.

This will keep team sizes very small.

2026 is going to be very interesting for the whole industry.

[Mitchell Hashimoto @mitchellh]

Slop drives me crazy and it feels like 95+% of bug reports, but man, AI code analysis is getting really good. There are users out there reporting bugs that don't know ANYTHING about our stack, but are great AI drivers and producing some high quality issue reports.

This person (linked below) was experiencing Ghostty crashes and took it upon themselves to use AI to write a python script that can decode our crash files, match them up with our dsym files, and analyze the codebase for attempting to find the root cause, and extracted that into an Agent Skill.

They then came into Discord, warned us they don't know Zig at all, don't know macOS dev at all, don't know terminals at all, and that they used AI, but that they thought critically about the issues and believed they were real and asked if we'd accept them. I took a look at one, was impressed, and said send them all.

This fixed 4 real crashing cases that I was able to manually verify and write a fix for from someone who -- on paper -- had no fucking clue what they were talking about. And yet, they drove an AI with expert skill.

I want to call out that in addition to driving AI with expert skill, they navigated the terrain with expert skill as well. They didn't just toss slop up on our repo. They came to Discord as a human, reached out as a human, and talked to other humans about what they've done. They were careful and thoughtful about the process.

People like this give me hope for what is possible. But it really, really depends on high quality people like this. Most today -- to continue the analogy -- are unfortunately driving like a teenager who has only driven toy go-karts.

Examples: https://t.co/n8xCcPYSjw

[Jesus del Valle @yeysus]

#StrangerThings5 just made me cry. A WONDERFUL 2026 Y’ALL !!

[Jesus del Valle @yeysus]

Alzheimers reversed in mouse models. If this works in humans, it is going to be a major milestone in the history of medicine. #AlzheimersDisease

[Eveline Ruehlin @enilev]

💥🧠 Study Finds Way to Reverse Alzheimer’s

@NeuroscienceNew
University Hospitals Cleveland
Case Western

Key Facts

📍Central #NAD+ Failure: Human and mouse Alzheimer’s brains showed a dramatic loss of NAD+, impairing essential cellular functions.

📍Reversal Achieved: Restoring NAD+ balance repaired pathology and fully recovered cognition even in mice with advanced disease.

📍New Treatment Pathway: The targeted drug #P7C3-A20 restored healthy NAD+ levels without the dangers linked to over-the-counter #NAD+ boosters.

👉https://t.co/oRlWHGnmz2
HT: Martha Boeckenfield (LI)

#Alzheimers #Neuroscience
#CES26 #HealthTech

@Khulood_Almani @Shi4Tech @jblefevre60 @mvollmer1 @IanLJones98 @EvanKirstel @Eli_Krumova @ipfconline1 @RLDI_Lamy @HaroldSinnott @CurieuxExplorer @gvalan @bulbi59 @Fabriziobustama @marcusborba @anand_narang @NevilleGaunt @JoannMoretti @Timothy_Hughes @margaretsiegien @Ym78200 @ahier @RosyCoaching @dinisguarda @Sharleneisenia @PawlowskiMario @FrRonconi @Nicochan33 @Fisher85M @andresvilarino @jeancayeux @SpirosMargaris @domingonarvaez1 @bamitav @baski_LA @AkwyZ @TerenceLeungSF @sonu_monika @SabineVdL @TravelFoodiesTV #CES2026 #CES #Memory #Dementia #Neurology #Aging #CES2026
Credit: Neuroscience News

[Jesus del Valle @yeysus]

Old but gold. How Fred Smith rescued FedEx from bankruptcy by playing blackjack in Las Vegas | Fox Business https://t.co/zIMdhD9GtN

[Neuralink @neuralink]

ALS is a neurodegenerative disease that gradually and relentlessly takes away bodily functions, such as the ability to speak.

With Neuralink, we aim to restore the voices of those who have lost them.

[Jesus del Valle @yeysus]

This and the Artificial Hivemind article: Same question to different AIs, converge into same answer. Echoes in AI: Quantifying lack of plot diversity in LLM outputs | PNAS https://t.co/dSnuOZah8a